Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Profit After Tax (2019 - 2025)

Avidity Biosciences' Profit After Tax history spans 7 years, with the latest figure at -$237.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 131.87% year-over-year to -$237.1 million; the TTM value through Dec 2025 reached -$684.6 million, down 112.42%, while the annual FY2025 figure was -$684.6 million, 112.42% down from the prior year.
  • Profit After Tax reached -$237.1 million in Q4 2025 per RNA's latest filing, down from -$174.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$23.8 million in Q1 2021 to a low of -$237.1 million in Q4 2025.
  • Average Profit After Tax over 5 years is -$75.6 million, with a median of -$52.4 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: crashed 291.85% in 2021, then decreased 2.92% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$38.5 million in 2021, then crashed by 30.96% to -$50.5 million in 2022, then dropped by 19.76% to -$60.4 million in 2023, then tumbled by 69.18% to -$102.3 million in 2024, then tumbled by 131.87% to -$237.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Profit After Tax are -$237.1 million (Q4 2025), -$174.4 million (Q3 2025), and -$157.3 million (Q2 2025).